National Research (NASDAQ:NRC) Reaches New 12-Month High – Should You Buy?

National Research Corporation (NASDAQ:NRC) reached a new 52-week high during mid-day trading on Friday . The company traded as high as $22.16 and last traded at $22.0950, with a volume of 52850 shares trading hands. The stock had previously closed at $21.30.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded National Research from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, January 12th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, National Research currently has an average rating of “Hold”.

National Research Stock Performance

The company has a current ratio of 0.53, a quick ratio of 0.53 and a debt-to-equity ratio of 5.31. The stock has a market cap of $503.44 million, a PE ratio of 31.74 and a beta of 0.47. The business’s 50-day moving average price is $17.85 and its 200-day moving average price is $15.49.

National Research (NASDAQ:NRC) last announced its earnings results on Monday, October 27th. The company reported $0.23 earnings per share for the quarter. National Research had a net margin of 11.76% and a return on equity of 98.26%. The company had revenue of $34.61 million during the quarter.

Institutional Investors Weigh In On National Research

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. QV Investors Inc. grew its stake in shares of National Research by 7.6% during the second quarter. QV Investors Inc. now owns 381,310 shares of the company’s stock worth $6,406,000 after acquiring an additional 26,950 shares during the last quarter. Hotchkis & Wiley Capital Management LLC boosted its stake in National Research by 7.9% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 292,400 shares of the company’s stock worth $3,737,000 after purchasing an additional 21,450 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of National Research by 86.2% in the second quarter. AQR Capital Management LLC now owns 201,396 shares of the company’s stock worth $3,383,000 after buying an additional 93,262 shares during the last quarter. Willis Investment Counsel grew its holdings in shares of National Research by 175.2% during the second quarter. Willis Investment Counsel now owns 180,999 shares of the company’s stock valued at $3,041,000 after buying an additional 115,221 shares during the last quarter. Finally, Creative Planning grew its holdings in shares of National Research by 319.2% during the second quarter. Creative Planning now owns 147,413 shares of the company’s stock valued at $2,477,000 after buying an additional 112,251 shares during the last quarter. 47.26% of the stock is currently owned by hedge funds and other institutional investors.

National Research Company Profile

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.